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Analytical determination of heroin, fentanyl and
fentalogues using high-performance liquid
chromatography with diode array and
amperometric detection†
Hadil M. Elbardisy, ab Christopher W. Foster, a Loanda Cumba,c
Lysbeth H. Antonides,a Nicolas Gilbert,ad Christopher J. Schoﬁeld,de Tarek S. Belal, f
Wael Talaat,b Oliver B. Sutcliﬀe, ad Hoda G. Daabeesg and Craig E. Banks *a
Over recent years there has been a progressive increase in the adulteration of common illicit street drugs,
such as heroin and cocaine, with fentanyl and its derivatives (fentalogues) being the cause of over doses
ending with fatal repercussions. Consequently, there is a need for the development of sensitive, selective
and reliable analytical protocols for their separation and quantiﬁcation. Herein, we report for the ﬁrst
time, a combination of high-performance liquid chromatography with a dual-diode array and
electrochemical (amperometric) detector achieved for the simultaneous detection and quantiﬁcation of
heroin (HRN), fentanyl and ten fentalogues; the amperometric detection is achieved using
a commercially available impinging jet ﬂow-cell that incorporates in-house screen-printed graphite
macroelectrodes (SPEs). Both protocols are analytically compared and contrasted in terms of their
experimental parameters and chromatographic conditions with the separation and quantiﬁcation being
optimized, with these protocols demonstrating a high sensitivity and reproducibility. The proposed
methods were successfully applied for the analysis of the investigated drugs of abuse, in the presence of
common adulterants (e.g. caﬀeine, paracetamol and benzocaine), co-formulated excipients (starch,
lactose, aerosil 200, etc.) and simultaneously within seized street samples.
Introduction
Fentanyl (Scheme 1), (N-phenyl-N-[1-(2-phenylethyl)piperidin-
4-yl]propanamide, 2c) is a synthetic narcotic analgesic,
a potent m-opioid receptor agonist that is one hundred times
more potent than heroin (HRN) (Scheme 1).1,2 Fentanyl was
primarily introduced by Janssen Pharmaceutica in the early
1960's as an intravenous anesthetic during surgical operations.1
In the late 1980's, the same pharmaceutical company developed
transdermal fentanyl patches under the trade name Duragesic®
to relieve pain in cancer patients.3 It was not until the 1970's
when the illicit use of “China Girl” or “China White” (alias given
to fentanyl and its analogues) started to appear in California
where it began to be substituted for HRN leading to unprece-
dented mortality rates.4 Over recent decades, adulteration of
common illicit street drugs with fentanyl (owing to its low
production cost, high potency and induced-euphoric properties)
has made it a favorable “high” in the recreational drug market.5
According to the U.S. Federal Control Substances Act 2017
published by the U.S. Department of Justice, fentanyl is classi-
ed as a Schedule II narcotic, since 1970. Recently, the Drug
Enforcement Administration (DEA) in the U.S. provisionally
listed structurally related fentanyl substances such as ace-
tylfentanyl (2b) and butyrfentanyl (2f) under Schedule I of the
Controlled Substances Act.6 Worldwide the fentanyl crisis has
proliferated at an unprecedented rate posing signicant public
health challenges. In the U.S., 1013 fentanyl-related deaths were
reported over the period 2005–2007, which were attributed to
fentanyl/HRN mixtures. In March 2017, China controlled four
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types of fentanyl analogues under the Chinese law, aer
a meeting held between the U.S. In Europe, according to
a commentary published in the International Journal of Drug
Policy,7 Sweden was the rst country to report 8 fentanyl-related
deaths in 1994. However, Estonia recorded the highest fentanyl
mortality rates in the EU, with an estimate of 1100 deaths over
the period 2005–2013; deaths peaked in 2012 and reached 170,
which was 11 times higher than the European average.7
Due to the high potency and dangerous impact of fentanyl
and its analogues worldwide, their quantitative determination
is of considerable importance. Within the literature, fentanyl is
mainly determined via two major techniques, either chroma-
tography (with the appropriate detector) or electrochemistry;
Table 1 provides a thorough overview of these methodologies
applied to the detection of fentanyl and its fentalogues. Chro-
matography and related techniques have extensively been re-
ported but are generally considered expensive and require
expert users for their eﬃcient operation. In the case of elec-
trochemical methodologies, these are more limited and are yet
be utilized for the separation of HRN, fentanyl and fentalogues.
Of note, from the inspection of Table 1, only one hybrid tech-
nique high-performance liquid chromatography-photolysis-
electrochemical detection8 has been utilized towards fentanyl
detection, however, only used for the analysis of 2c.
Herein, we develop for the rst time, a combination of high-
performance liquid chromatography-diode array detection
(HPLC-DAD) and high-performance liquid chromatography-
amperometric detection (HPLC-AD) methods for the
separation and quantication of fentanyl (2c), ten fentalogues
(2a, 2b, 2d–2k) and HRN. This approach uses screen-printed
graphite macroelectrodes (SPEs), as they are an advantageous
electrochemical sensing platform that can be utilized in various
quantication methods, owing to their economy of scales,
simplicity and reproducibility.9–12
Results and discussion
Electrochemical measurement of the target analytes using
cyclic voltammetry
Fig. 1 depicts the individual voltammetric proles for fentanyl
(2c), HRN and COC utilizing SPEs. In consideration of previous
literature, fentanyl (2c)8,13 and cocaine (COC) (Scheme 1),14,15 as
observed within Fig. 1, likely undergo an irreversible electro-
chemical oxidation/process as a result of the tertiary amine but
in fact is likely more complex with the oxidation peak con-
taining a contribution from more complex processes with
formation of hydroxylated compounds and oxidation to give
quinone imine groups. Since this is the rst electrochemical
report of the electrochemical oxidation of fentanyl, the exact
mechanism needs further elucidation. Similarly, the observed
electrochemical signature for heroin (HRN) is likely due to the
irreversible electrochemical oxidation of the tertiary amine
corresponding to the formation of a secondary amine.16,17
Fig. S1† displays typical cyclic voltammograms for each of HRN,
COC, fentanyl and fentalogues, at pH 2.0, 7.0 and 10.0, utilizing
SPEs. It is apparent that at pH 2.0 there are no apparent
Scheme 1 Chemical synthesis and structures of fentanyl (2c), fentalogues (2a, 2b, 2d–2k), heroin (HRN) and cocaine (COC).
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electrochemical oxidation waves/signal of the target analytes
(Fig. S1A†) within the accessible electrochemical window.
Additionally Fig. S1B and S1C† overview the response of the
HRN, COC, fentanyl and fentalogues in pH 10 and 7; Table S1†
compares the peak potentials of all the drug analytes at the pH's
2, 7 and 10. Note that analytically useful voltammetric peaks are
obtained for all the analytes in pH 7.0; consequently, pH 7.0 was
chosen as the optimum pH for the voltammetric analysis of the
target analytes/drugs. In summary, it is clear that in consider-
ation of the peak potentials of all the studied drugs/analytes,
they all overlap, in terms of electrochemical oxidation poten-
tials, so if they were all present in a real sample, such as in the
case of a street sample with an unknown composition, as is
typically the case, all analytes present within the sample cannot
be unambiguously determined. Due to the inability of a direct
electroanalytical approach to separate and quantify HRN, (2c)
and fentalogues (2a, 2b, 2d–2k), attention was turned to the use
of chromatography to separate and analyze the drugs of
interest, using high-performance liquid chromatography with
DAD and AD detection.
Optimization of the chromatographic conditions
Conguration and arrangement of HPLC-DAD and HPLC-AD
protocol. Following Zuway et al., the best arrangement of the
detectors is by placing the DAD preceding the AD and con-
necting them via PTFE tubing (230  1.6 mm, i.d. 0.3 mm,
internal volume: 16.25 mL), as this conguration reduces the
system back-pressure thus minimizing leakages from the ow-
cell occurring when the detectors arrangement is switched.9
Also, Zuway et al., reported using two types of ow-cells for
amperometric analysis of synthetic cathinones namely
a commercially available impinging jet ow-cell and custom-
made iCell channel ow-cell, however, in the present work
only the impinging jet ow-cell was used, as Zuway et al.,
demonstrated that iCell ow-cell is not as sensitive due to the
large internal chamber volume accommodating the SPE,Ta
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Fig. 1 Typical cyclic voltammograms obtained separately for (2c),
HRN and COC; solution composition: 50 mg mL1 of each drug within
a 0.04 M B–R buﬀer pH 7.0; scan rate: 50 mV s1.
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increasing the sample dispersion, diluting the analytes, there-
fore reducing the SPEs sensor sensitivity via mass transfer/
diﬀusion to the electrode surface.9,18–20
Stationary phase. Diﬀerent column types (packing material)
were explored for the simultaneous and eﬃcient separation of
HRN, fentanyl and its fentalogues, in order to achieve optimal
separation, good resolution (Rs) between peaks, reasonable
retention and run time and to obtain sharp symmetric peaks.
The tested columns were: Phenomenex, Hyperclone C18 (150 
4.6 mm, i.d. 5 mm), Hypurity™ Elite hypersil C18 (100  3 mm,
i.d. 3 mm), Greysil C8 (100  3.2 mm, i.d. 5 mm), ACE 5 C18-AR
(150  4.6 mm, i.d. 5 mm) and Eclipse XDB-C8 (150  4.6 mm,
i.d. 5 mm). The rst column retained the drugs for a signicantly
long time and requires the acetonitrile ratio to increase to 40%
to have a reasonable run time, however this will aﬀect the
electrochemical detection, which favors a low ratio of organic
present. The second and third columns eluted with the drugs
overlapping together within just 15 minutes; decreasing the
ratio of acetonitrile to 20% resulted in the elution of all drugs as
very broad peaks. The fourth column eluted the drugs within
a reasonable run time as sharp symmetric peaks, however,
isovaleryl- and valerylfentanyl (2i and 2j respectively) overlapped
together and eluted as one broad peak. The h column,
Eclipse XDB-C8 (150  4.6 mm, i.d. 5 mm), fullled all the
chromatographic requirements and was chosen for this study.
Mobile phase. Previous papers for the chromatographic
determination of fentanyl, reports the use of formic acid or
ammonium formate as the aqueous phase with acetonitrile as
the organic modier.6–8 Therefore, an isocratic mobile phase of
ammonium formate and acetonitrile was favored over gradient
elution programs despite of their advantages of shortening the
analysis time and optimizing the separation. This was explained
by Zuway et al., who adapted an isocratic method for HPLC-AD,
to prevent the uctuation of electrolyte composition during
electrochemical detection, and used reduced ratio of organic
modier (10 mM ammonium acetate : methanol 70 : 30% v/v)
in combination with a suitable electrolyte (100 mM KCl).1
Similarly, we used a mobile phase consists of 20 mM ammo-
nium formate : acetonitrile 70 : 30% v/v and added 100 mMKCl
to the aqueous phase as an electrolyte. Attempts to decrease the
organic modier percentage were unfavorable as it aﬀected the
peaks symmetry and prolonged the run time over 30 minutes.
Ionic strength of ammonium formate buﬀer. The eﬀect of
the ionic strength of the chosen buﬀer was studied using 5, 10,
20, 30, 40, 50 mM ammonium formate. In HPLC-DAD, it was
found that increasing the molarity of the buﬀer increases the
baseline noise, however, the total run time decreases and using
Fig. 2 (A) Representative HPLC-DAD chromatograms for a solution containing 50 mgmL1 of each of HRN, fentanyl (2c) and fentalogues (2a, 2b,
2d–2k) using an Eclipse XDB-C8 column (150 4.6 mm, i.d. 5 mm); mobile phase: acetonitrile : 20 mM ammonium formate–100mM potassium
chloride buﬀer (pH 7.0) (30 : 70% v/v); ﬂow rate 1.5 mL min1, detector wavelength (UV): 205 nm and column temperature: 25 C. (B) Repre-
sentative amperogram for a solution containing 50 mg mL1 of each of HRN, fentanyl and its 10 derivatives obtained using HPLC-AD ﬂow cell
system. (C) HPLC-DAD chromatogram for a solution containing 50 mg mL1 of each of COC, fentanyl and its 10 derivatives. (D) Representative
amperogram for a solution containing 50 mg mL1 of each of COC, fentanyl and its 10 derivatives obtained using HPLC-AD ﬂow cell system.
This journal is © The Royal Society of Chemistry 2019 Anal. Methods
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a very low molarity resulted in fronted peaks. In the case of
HPLC-AD, changing the buﬀer molarity did not aﬀect the
amperograms or the amperometric response (peak current, mA).
Therefore, 20 mM ammonium formate was chosen since it gives
the best compromise in terms of peak shape and symmetry and
total run time (30 minutes).
pH of the aqueous phase. Aer selection of the best buﬀer
and optimising its molarity, the eﬀect of pH of the aqueous
phase (20 mM ammonium formate + 100 mM KCl) was studied
over the range 3.0–8.0 (at 1 pH unit increments). In case of
HPLC-DAD, it was found that using low pHs (i.e. pH 3.0, 4.0 and
5.0) resulted in a noisy baseline, asymmetric peaks, short run
time, HRN and methoxyacetylfentanyl (2a) peaks overlap
together and cybutylfentanyl (2g) and benzoylfentanyl (2h)
eluted as one broad peak. Observing HPLC-DAD chromato-
grams at pH 7.0 and 8.0, it was found that pH 7.0 gave the best
peak symmetry with all peaks being resolved with a total run
time of 30 minutes, however, using pH 8.0 prolonged the run
time (last peak eluted at 74 minutes) and the baseline became
noisy. In HPLC-AD, cybutylfentanyl (2g) and benzoylfentanyl
(2h) are overlapped the same way in HPLC-DAD, by increasing
the pH above 3.0 they begin to separate, and they are completely
resolved at pH 6.0. The electrochemical oxidation of HRN at
pH's 3.0 and 4.0 (within the HPLC-AD ow cell system) does not
give rise to any suﬃcient detection, however at pH 5.0 a minia-
turized peak appears but upon changing the pH to 8.0 the
amperometric signal increases to its maximum. Nonetheless,
all the fentalogues recorded the highest current intensity at pH
7.0. It also important to note, that the prolonged run time at pH
8.0, eluded us from using it. Therefore, pH 7.0 was the optimum
pH for this study.
Detection wavelength. In order to quantify HRN, fentanyl
and its derivatives accurately and maximize the HPLC-DAD
sensitivity; the photo diode array detector (DAD) was set at
205 nm (lmax for HRN, fentanyl, and it's fentalogues) (Fig. S2A
and S2B†), which coincides with the literature that used the
same wavelength for fentanyl9 and HRN10 quantication.
Linear velocity of mobile phase. Linear velocity of the mobile
phase is an important factor to be studied as it aﬀects peak
symmetry, resolution (Rs) between closely eluted peaks and total
run time. The studied ow rates were: 1.1, 1.3, 1.5, 1.7
mL min1. In HPLC-DAD, symmetry of the peaks was found to
Table 2 Summary of HPLC-DAD data for the quantiﬁcation of HRN, fentanyl (2c) and fentalogues (2a, 2b, 2d–2k) obtained using Eclipse XDB-C8
column (150 4.6mm, i.d. 5 mm); mobile phase [acetonitrile : 20mM ammonium formate–100mM potassium chloride buﬀer (pH 7.0) (30 : 70%
v/v)]; ﬂow rate ¼ 1.5 mL min1; detector wavelength (UV) ¼ 205 nm; and column temperature ¼ 25 C
Parameters
Analyte
HRN (2a) (2b) (2c) (2d) (2e) (2f) (2g) (2h) (2i) (2j) (2k)
R2a 0.999b 0.999c 0.999d 0.999e 0.999f 0.999g 0.999h 0.999i 0.999j 0.999k 0.999l 0.999m
LODn
(mg mL1)
16.20 
102
22.49 
102
24.47 
102
41.67 
102
49.67 
102
68.80 
102
74.63 
102
95.54 
102
96.77 
102
1.15 1.35 1.36
LOQo
(mg mL1)
54.0 
102
74.96 
102
81.57 
102
1.39 1.66 2.29 2.49 3.18 3.23 3.85 4.50 4.55
Precision (% RSD, n ¼ 6)
5 mg mL1 0.29 0.21 0.78 0.39 0.40 0.43 0.74 0.56 0.28 0.34 1.0 0.91
10 mg mL1 0.42 0.42 0.94 0.86 0.64 0.42 1.0 1.0 0.75 0.53 0.55 0.53
40 mg mL1 0.42 0.54 0.75 1.0 0.64 0.38 0.62 0.10 0.54 0.59 0.99 1.0
80 mg mL1 0.90 0.77 0.66 0.55 0.61 0.83 0.74 0.55 0.58 0.55 0.46 0.46
120 mg mL1 0.96 0.73 0.98 0.59 0.81 0.79 0.67 0.99 0.92 0.88 0.95 0.82
System suitability parameters
tR  SD (min)p
(n ¼ 6)
2.79 
0.03
4.09 
0.04
4.79 
0.02
8.10 
0.04
10.79 
0.08
13.20 
0.05
14.26 
0.07
18.08 
0.01
20.65 
0.05
25.50 
0.03
27.64 
0.04
29.42 
0.06
RRTq 0.34 0.50 0.59 1.0 1.33 1.63 1.76 2.23 2.55 3.15 3.41 3.63
k0r 2.10 3.54 4.32 8.0 10.99 13.67 14.84 19.09 21.94 27.33 29.71 31.69
N (plates)s 2111 5165 6624 8396 8930 9238 9610 9563 9560 9853 10 223 10 196
HETP (m)t 7.11 
105
2.90 
105
2.26 
105
1.79 
105
1.68 
105
1.62 
105
1.56 
105
1.57 
105
1.57 
105
1.52 
105
1.47 
105
1.47 
105
Rs
u — 4.69 2.82 10.41 6.57 4.75 1.88 5.74 3.23 5.13 2.00 1.59
As
v 1.29 1.43 1.33 1.00 0.92 0.91 0.88 0.82 0.88 0.80 0.93 0.84
aw — 1.69 1.22 1.85 1.37 1.24 1.09 1.29 1.15 1.25 1.09 1.07
a R2: co-eﬃcient of regression. b y¼ 25.543x 21.487. c y¼ 21.14x 7.931. d y¼ 22.659x 23.03. e y¼ 21.87x 25.32. f y¼ 23.737x 31.553. g y¼
21.89x  40.11. h y ¼ 22.15x  61.48. i y ¼ 20.74x  44.90. j y ¼ 20.74x  44.90. k y ¼ 18.94x  40.41. l y ¼ 18.70x  43.54. m y ¼ 18.51x  44.17.
n LOD: limit of detection. o LOQ: limit of quantitation. p tR: retention time in minutes for drugs eluted from the chromatographic column (Method
I). q RRT: relative retention time (determined with respect to (2c) retention time obtained from Method I). r k0: capacity factor. s N: number of
theoretical plates expressed in plates per m. t HETP: height equivalent to theoretical plate expressed in m. u Rs: resolution between two
successive eluted peaks. v As: asymmetry factor.
w a: relative retention factor.
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be good in all of the studied ow rates and the diﬀerence
between the total run-time in the four ow rates was not
signicantly big. Therefore, resolution (Rs) between the closest
two peaks in the chromatogram was the key factor in choosing
the ow rate. The closest two eluted peaks are the last two peaks
in the chromatogram (valerylfentanyl (2j) and cyclo-
pentylfentanyl (2k)), ow rate ¼ 1.7 mL min1 gave the shortest
run time but the resolution (Rs) between valerylfentanyl (2j) and
cyclopentylfentanyl (2k) dropped to 1.49. Therefore, ow rate
1.5 mL min1 was chosen to not prolong the run time (total run
time ¼ 30 minutes) and the resolution (Rs) between the last two
eluting peaks was acceptable (Rs ¼ 1.54). In HPLC-AD, the
mobile phase ow rate did not have any signicant eﬀect on the
analytes' amperometric response (peak current, mA), i.e. peak
heights (current intensity, mA) of all drugs remained unchanged
by changing the ow rate (Fig. S3A†).
Optimization of the electrochemical potential for HPLC-AD.
In order to increase the sensitivity of amperometric measure-
ments and obtain optimum detector response, the potential has
to be optimized. From the recent data we obtained from cyclic
voltammetry (CV) it was apparent that each of HRN, fentanyl
and its derivatives has an anodic peak at Epz +0.9 V, thus the
amperometric response (peak current, mA) was measured as
a function of the anodic potential (V) over the range (E¼ +0.8 to
+1.2 V). Using potential of +0.8 V resulted in a poor signal for all
analytes that increased gradually until reaching a maximum
value at potential of +1.0 V (Fig. S3B†).
Following the optimization of all the experimental/
chromatographic conditions, typical HPLC-DAD chromato-
grams and HPLC-AD amperograms for HRN and fentalogues
are presented in Fig. 2A and B, respectively. Fig. 2C and D
represent HPLC-DAD chromatograms and HPLC-AD ampero-
grams for COC, (2c) and fentalogues (2a, 2b, 2d–2k). It should
be noted that HRN and COC elute at very similar retention times
(tR) (COC; tR in HPLC-DAD ¼ 2.65 min), therefore, analysis of
HRN and COC in the same sample is likely not feasible. The
proposed analytical methodologies were validated according to
the ICH recommendations;21 all validation parameters are pre-
sented in Tables 2, 3, S2 and S3.†
Analytical performance was next considered via calibration
curves for the HPLC-DAD and HPLC-ADmethods. The LOD's (3-
sigma) are found to range from 0.16–1.36 mg mL1 and 0.45–
2.93 mgmL1, for HPLC-DAD and HPLC-AD, respectively (Tables
2 and 3). The LOQ's (10-sigma) range from 0.54–4.55 mg mL1
and 1.49–9.76 mg mL1, for HPLC-DAD and HPLC-AD, respec-
tively (Tables 2 and 3). However, through comparing the LOD
and LOQ of both analytical approaches we can conclude that
HPLC-DAD is relatively more analytically sensitive than that of
the HPLC-AD. All system suitability parameters are listed in
Tables 2 and 3. The selectivity of both methods was investigated
by injecting potential adulterants commonly found in street
samples, which are: caﬀeine (Cf), paracetamol (Pc) and benzo-
caine (Bz). Unfortunately, the chromatographic approach could
not separate (Cf) from (Pc), as the two peaks elute at similar
retention times. Consequently, two adulterated solutions were
Table 3 Summary of HPLC-AD validation data for the quantiﬁcation of HRN, fentanyl (2c) and fentalogues (2a, 2b, 2d–2k) obtained utilizing
HPLC-AD. The chromatographic conditions are: Eclipse XDB-C8 column (150  4.6 mm, i.d. 5 mm); mobile phase [acetonitrile : 20 mM
ammonium formate–100 mM potassium chloride buﬀer (pH 7.0) (30 : 70% v/v)]; ﬂow rate ¼ 1.5 mL min1; detector wavelength (UV) ¼ 205 nm;
and column temperature ¼ 25 C
Parameters
Analyte
HRN (2a) (2b) (2c) (2d) (2e) (2f) (2g) (2h) (2i) (2j) (2k)
R2a 0.997b 0.996c 0.996d 0.999e 0.997f 0.996g 0.998h 0.999i 0.998j 0.996k 0.999l 0.998m
LODn (mg mL1) 0.45 0.48 0.48 0.77 0.91 1.19 1.28 1.71 1.68 2.60 2.78 2.93
LOQo (mg mL1) 1.49 1.61 1.61 2.58 3.04 3.95 4.27 5.71 5.59 8.68 9.26 9.76
Precision (%RSD, n ¼ 6)
10 mg mL1 0.01 0.73 0.76 0.85 0.40 0.95 0.05 0.48 0.56 0.20 0.32 0.89
40 mg mL1 0.10 0.57 0.06 0.55 0.38 0.13 0.49 0.81 0.16 0.41 0.79 0.06
60 mg mL1 0.30 0.45 0.06 0.06 0.05 0.23 0.29 0.31 0.19 0.83 0.85 0.32
80 mg mL1 0.20 0.15 0.09 0.06 0.13 0.11 0.08 0.33 0.11 0.20 0.77 0.06
100 mg mL1 0.11 0.65 0.40 1.05 0.14 0.17 0.21 0.01 0.00 0.31 0.61 0.49
120 mg mL1 0.92 0.84 0.33 0.63 0.27 0.60 0.82 0.21 0.31 0.93 0.96 0.32
System suitability parameters
tR  SD (min)p (n
¼ 6)
2.80 
0.03
4.1 
0.04
4.80 
0.02
8.11 
0.04
10.80 
0.08
13.21 
0.05
14.27 
0.07
18.09 
0.01
20.66 
0.05
25.51 
0.03
27.65 
0.04
29.43 
0.06
RRTq 0.35 0.51 0.59 1 1.33 1.63 1.76 2.23 2.55 3.15 3.41 3.63
N (plates)r 2101 5150 6620 8380 8920 9230 9600 9555 9545 9850 10 218 10 188
Rs
s — 4.69 2.82 10.41 6.57 4.75 1.86 5.74 3.18 5.10 1.88 1.50
a R2: co-eﬃcient of regression. b y¼ 0.006x + 0.007. c y¼ 0.012x 0.041. d y¼ 0.011x 0.041. e y¼ 0.006x + 0.017. f y¼ 0.006x 0.015. g y¼ 0.003x
+ 0.026. h y ¼ 0.005x  0.025. i y ¼ 0.004x  7  105. j y ¼ 0.003x  0.001. k y ¼ 0.003x + 0.002. l y ¼ 0.002x  0.006. m y ¼ 0.002x  0.004. n LOD:
limit of detection. o LOQ: limit of quantitation. p tR: retention time in minutes for drugs eluting from the ow-cell (Method II).
q RRT: relative
retention time (determined with respect to (2c) retention time obtained from Method II). r N: number of theoretical plates expressed in
plates per m. s Rs: resolution between two successive eluted peaks.
This journal is © The Royal Society of Chemistry 2019 Anal. Methods
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prepared; one containing 50 mg mL1 of each of (Cf), (Bz) and
the twelve investigated drugs, while the second solution was the
same but (Cf) was substituted with (Pc). Fig. 3A and B depict the
HPLC-DAD chromatogram and HPLC-AD amperogram for the
rst adulterated solution and Fig. 3C and D present the HPLC-
DAD chromatogram and HPLC-AD amperogram for the second
adulterated solution, respectively. The HPLC-AD amperogram is
presented within Fig. 3D, which depicts a peak for (Pc) and
a peak for (Bz) while the HPLC-AD amperogram, illustrated in
Fig. 3B, gives rise to a sole peak for (Bz). Such a response is due
to (Cf) undergoing an irreversible electrochemical oxidation
process, at Ep z +1.4 V,22,23 however, herein, HPLC-AD
measurements were conducted at Ep ¼ +1.0 V (vs. Ag/AgCl)
hindering the oxidation of (Cf). Finally, the specicity of both
analytical methodologies was tested upon injecting a solution
containing 300 mg mL1 of potential diluents commonly found
in pharmaceutical formulations (D-glucose, D-fructose, sucrose,
lactose, starch, aerosil 200, sodium lauryl sulfate, stearic acid
and sodium carboxymethyl cellulose). It was found that this
solution did not show any peak in either HPLC-DAD chro-
matogram (Fig. S4A†) or HPLC-AD amperogram (Fig. S4B†).
Also, a solution containing 300 mg mL1 of excipients and 50 mg
mL1 of the investigated drugs was injected into the HPLC and
the magnitude of the response (peak area and peak heights) of
each compound was monitored for both methods (Fig. S5†). It
was found that the added excipients did not interfere and did
not aﬀect the analytical sensing of the investigated drugs by
both methods; the additives added were UV-inactive and elec-
trochemically inert. This demonstrates the high specicity and
selectivity of the promised sensing protocols.
Three seized samples of suspected HRN, were provided
under license by Greater Manchester Police and tested using
our proposed HPLC-AD methodology in order to test the
viability of the proposed protocol (as described in the Experi-
mental section). As presented in Table 4, analysis of a 2 mgmL1
HSS1 solution resulted in a % w/w equals to 1.66  0.02 and 1.48
 0.02 for (2c), using HPLC-DAD and HPLC-AD, respectively
(Table 4). Results for HRN% were strongly correlated with those
obtained with GC-MS, where the obtained % w/w for HRN ¼
26.70  0.61, however, the proposed methods overestimated
(2c)% when compared with that of GC/MS, (2c)% ¼ 0.26  1.16
(Table 4). The results obtained by HPLC-DAD and HPLC-AD
methodologies when analyzing HSS2, (containing HRN, (Cf)
and (Pc)) and HSS3 (containing HRN only) were in a good agree-
ment with each other: HRN % w/w in HSS2 ¼ 29.09  0.57 and
27.42  0.27 using HPLC-DAD and HPLC-AD, respectively (Table
4); HSS3, HRN % w/w ¼ 60.09  0.36 and 58.92  0.83 using
HPLC-DAD and HPLC-AD, respectively (Table 4). When
Fig. 3 (A) Representative HPLC-DAD chromatograms for a solution containing 50 mg mL1 of each of caﬀeine (Cf), HRN, benzocaine (Bz),
fentanyl (2c) and its 10 derivatives using Eclipse XDB-C8 column (150  4.6 mm, i.d. 5 mm); mobile phase: acetonitrile : 20 mM ammonium
formate–100 mM potassium chloride buﬀer (pH 7.0) (30 : 70% v/v); ﬂow rate 1.5 mL min1, detector wavelength (UV): 205 nm and column
temperature: 25 C. (B) Representative amperogram for a solution containing 50 mgmL1 of each of caﬀeine (Cf), HRN, benzocaine (Bz), fentanyl
and its 10 derivatives obtained using HPLC-AD ﬂow cell system. (C) HPLC-DAD chromatogram for a solution containing 50 mg mL1 of each of
paracetamol (Pc), HRN, benzocaine (Bz), fentanyl and fentalogues. (D) Representative amperogram for a solution containing 50 mg mL1 of each
of paracetamol (Pc), HRN, benzocaine (Bz), (2c) and fentalogues using HPLC-AD ﬂow cell system.
Anal. Methods This journal is © The Royal Society of Chemistry 2019
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comparing those results with GC/MS, we nd that HRN% w/w¼
29.50  0.52 and 62.70  0.75 for HSS2 and HSS3, respectively,
emphasizing the reliability of the proposed protocol. Note that
HSS1 and HSS2 have (Pc) and (Cf), both adulterants, which elute
together as a single peak using theHPLC-DAD, whereas, inHPLC-
AD only the (Pc) peak was visible.
In summary, in comparison of the two proposed detection
protocols, there are no signicant diﬀerences between them
and both give rise to the reliable quantication of the target
analytes. However, HPLC-AD demonstrates a slight underesti-
mation in its values, which can be attributed to its relatively
lower sensitivity comparing with the HPLC-DAD, but it is still
suitable and suﬃcient for the quantication of heroin, fentanyl
and fentalogues providing an analytically competitive protocol.
Conclusions
For the rst time, the analytical determination of HRN, fentanyl
(2c) and fentalogues (2a, 2b, 2d–2k) is reported using a dual
HPLC-DAD and HPLC-AD protocol employing a commercially
available impinging jet ow-cell, incorporating SPEs. This
methodology demonstrates high accuracy, precision and is in
a good agreement with traditional HPLC-DAD. This HPLC-AD
technique is the rst to be used as a precursor/screening
method for forensic samples. In addition, this method was
successfully applied for the analysis of the target analytes
without interference of common formulated excipients or
potential adulterants found in street samples.
Experimental section
Chemicals and materials
All reagents are of commercial quality (Sigma-Aldrich, Gilling-
ham, UK or Fluorochem Limited, Hadeld, UK) and used
without further purication. All aqueous solutions were
prepared with Milli-Q deionized water of resistively$ 18.2 U cm
(Millipore system). All solutions (unless stated otherwise) were
vigorously degassed, with highly pure nitrogen to remove
oxygen prior to analysis. Solvents (Fisher Scientic, Lough-
borough, UK) were dried, where necessary, using standard
procedures. The target compounds (2a–2k) were synthesized,
from 4-ANPP (1), using an adaptation of the method reported by
Valdez et al.24 and obtained as stable, oﬀ-white powders
(Scheme 1). The hydrochloride salts were determined to be
soluble (10 mg mL1) in deionised water, methanol and dime-
thylsulfoxide. To ensure the authenticity of the materials
utilized in this study the synthesized samples were structurally
characterized (see ESI† for more details) by both 1H-NMR and
13C-NMR and the purity of all samples was conrmed by NMR
and GC-MS (>99.5% in all cases). 1H-NMR and 13C-NMR spectra
were acquired on a JEOL AS-400 (JEOL, Tokyo, Japan) NMR
spectrometer operating at a proton resonance frequency of 400
MHz and referenced to the residual solvent peak (d6-DMSO:
1H-
NMR d ¼ 2.50 ppm, 13C-NMR d ¼ 39.52 ppm). Three seized
samples of heroin were provided by Greater Manchester Police,
in accordance with license requirements and agreed proce-
dures. Details of the street samples utilized are presented
within the ESI.†
Instrumentation
High performance liquid chromatography-diode array
detection (HPLC-DAD). Reverse phase HPLC was performed
with an integrated Agilent HP Series 1100 Liquid Chromatog-
raphy Instrument (Agilent Technologies, Wokingham, UK),
consisting of an Agilent 1100 Series Quaternary pump G1310A
(Serial DE80301064), an Agilent 1100 Series Vacuum Degasser
G1322A (Serial JP73017007) and an Agilent 1100 Series Diode
Array detector G1315A (Serial DE74603601), which was moni-
tored at a wavelength of 205 nm. The LC system is equipped
with Agilent 1100 Series Thermostated Column Compartment
G1316A (Serial DE91810205) controlled at 25 C, and a 100-place
auto injector G1313A (Serial DE54901543), with an injection
volume of 10.0 mL. The stationary phase used was an Eclipse
XDB-C8 column (4.6  150 mm; i.d. particle size: 5 mm; Ger-
many). The mobile phase was [acetonitrile : 20 mM ammonium
formate–100 mM potassium chloride buﬀer (pH 7.0), 30 : 70%
v/v] owing at a rate of 1.5 mL min1. The LC system was con-
nected to a computer loaded with Agilent Chemstation (Ver.
10.02) soware (Agilent Technologies, Wokingham, UK) for
data analysis.
Table 4 Comparison of data obtained using HPLC-DAD, HPLC-AD and GC/MS methodologies for the analysis of seized street samples
Method of
detection
Detected drugs of abuse
HPLC-DAD (Method I) HPLC-AD (Method II) GC/MS
Analyzed
street
sample
HRN (% w/w)
 SDa
RSDb
(%)
(2c) (% w/w)
 SDa
RSDb
(%)
HRN (% w/w)
 SDa
RSDb
(%)
(2c) (% w/w)
 SDa
RSDb
(%)
HRN (% w/w)
 SDa
RSDb
(%)
(2c) (% w/w)
 SDa
RSDb
(%)
tR (min)  SD 2.79  0.03 1.08 8.10  0.05 0.62 2.80  0.03 1.07 8.11  0.05 0.62 12.75  0.02 0.16 13.84  0.003 0.02
HSS1 26.64  0.31 1.16 1.66  0.02 1.20 24.16  0.18 0.75 1.48  0.02 1.35 26.70  0.61 2.28 0.26  0.003 1.15
HSS2 29.09  0.57 1.96 n.d.c n.d.c 27.42  0.27 0.98 n.d.c n.d.c 29.50  0.52 1.76 n.d.c n.d.c
HSS3 60.09  0.36 0.60 n.d.c n.d.c 58.92  0.83 1.41 n.d.c n.d.c 62.70  0.75 1.20 n.d.c n.d.c
a Mean  SD of obtained % w/w of three determinations of each detected drug in each street sample. b Percentage relative standard deviation of
obtained % w/w of three determinations of each detected drug in each street sample. c n.d. ¼ not detected.
This journal is © The Royal Society of Chemistry 2019 Anal. Methods
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High-performance liquid chromatography-amperometric
detection (HPLC-AD). The HPLC was coupled, in sequence, to
a commercially available impinging jet ow cell obtained from
Dropsens, Spain (product code: DRP-FLWCL-TEF-71306; 3.3 
6.0  3.3 cm, ow chamber volume ¼ 8 mL) housing the SPE.
The SPEs utilized in this part were fabricated in-house as
previously mentioned above.9,25 Amperometric measurements
were carried out using a Palmsens Emstat3 (Palmsens BV, The
Netherlands) potentiostat/galvanostat and controlled by
PSTrace (version 4.4) soware. All the amperometric measure-
ments were carried out at 25 C using the following parameters:
(i) potential (E, +1.0 V vs. Ag/AgCl); (ii) equilibration time (t-
equilibration, 10.0 s); (iii) data interval (t-interval, 0.08 s); (iv)
current range (100 nA to 1 mA) and (iv) total run time (t-run,
3000 s).
Preparation of the mobile phase [acetonitrile : 20 mM
ammonium formate–100 mM potassium chloride buﬀer (pH
7.0), 30 : 70% v/v]. The buﬀer system (20 mM ammonium
formate–100 mM potassium chloride) was prepared into a 2.0 L
volumetric ask by dissolving 2.52 g of ammonium formate and
14.91 g of potassium chloride in ultrapure deionized water, the
pH was adjusted by the dropwise addition of 0.1 M NaOH to pH
7.0. Aerwards, appropriate proportions of each of the buﬀer
and organic modier were mixed to obtain a 2.0 L mobile phase
of the desired ratio. Prior to use, the mobile phase was vacuum
ltered through a 0.45 mm pore lter paper and degassed for
10 min at 25 C using an ultrasonic bath.
Preparation of standard stock solution and calibration curve
for HPLC-DAD and HPLC-AD. 12.5 mg of each of HRN, fentanyl
hydrochloride (2c) and its fentalogues (2a, 2b, 2d–2k) were
weighted accurately into a 25.0 mL clear glass volumetric ask
and diluted to volume with mobile phase to give a stock solution
containing 0.5 mg mL1 of each drug (S). Working solutions for
calibration standards were prepared by further dilution of the
latter solution (S) with the mobile phase to give solutions con-
taining 5 mg mL1, 10 mg mL1, 20 mg mL1, 40 mg mL1, 60 mg
mL1, 80 mgmL1, 100 mgmL1 and 120 mgmL1 of each analyte.
Working solutions were injected directly into the HPLC and the
peak areas (for HPLC-DAD analysis) and peak heights (for HPLC-
AD analysis) of the studied drugs are plotted against their cor-
responding concentrations to construct the calibration curves. All
solutions were covered with aluminum foil and the stock solution
was kept in the refrigerator at 4 C for two weeks.
Selectivity standards. 12.5 mg of caﬀeine (Cf), paracetamol
(Pc) and benzocaine (Bz) were weighted separately into three
25.0 mL glass volumetric asks and diluted to volume with the
mobile phase to obtain a stock solution of 0.5 mgmL1 for each
component. 0.5 mL from each stock solution were taken sepa-
rately into three 5.0 mL volumetric ask, completed to volume
with themobile phase and each solution was injected separately
into the HPLC to monitor the retention time (tR) for each
compound. 0.5 mL from both caﬀeine (Cf) and benzocaine (Bz)
and/or paracetamol (Pc) and benzocaine (Bz) were added to
a 5.0 mL volumetric ask containing 0.5 mL of the drug stock
solution (S), the asks were completed to the mark with the
mobile phase and injected into the HPLC.
Specicity standards. 10.0 mg of each of D-glucose, D-fruc-
tose, sucrose, lactose, starch, aerosil 200, sodium lauryl sulfate,
stearic acid and sodium carboxymethyl cellulose were weighted
accurately into one 20.0 mL glass volumetric asks, dissolved in
the mobile phase, sonicated for 20 minutes and diluted to
volume with the same solvent to obtain a stock solution of
0.5 mg mL1 for each component. 3.0 mL of the prepared
solution were transferred into a 5.0 mL volumetric ask, diluted
to the mark with the mobile phase and injected into the HPLC.
Another 3.0 mL of the excipient solution were added to a 5.0 mL
volumetric ask containing 0.5 mL from the drug stock solution
(S), the ask wasmixed, andmade up to volume with the mobile
phase and injected into the HPLC.
Application of the HPLC-DAD and HPLC-AD methods
towards seized street samples. Three HRN containing street
samples seized by Greater Manchester Police were brought to
our authorized lab. The homogenized samples were arbitrarily
labeled as heroin street sample 1 (HSS1), heroin street sample 2
(HSS2) and heroin street sample 3 (HSS3). 12.5 mg from each
street sample were accurately weighted (in triplicate) and added
separately into 25.0 mL volumetric asks, diluted with the
mobile phase, sonicated for 20 minutes and made to the mark
with the latter solvent. The obtained solutions were ltered
through 0.2 mm PTFE syringe lters and 1.0 mL from each
ltered solution was transferred separately into 5.0 mL volu-
metric asks, made to volume with the mobile phase and
injected into the HPLC system. The rst street sample (HHS1)
was analyzed again (in triplicate) by preparing a more concen-
trated solution consisting of 50.0 mg of HHS1 homogenized
powder added to a 25.0 mL volumetric ask, diluted with the
eluent, sonicated for 20 minutes, completed to the mark with
the mobile phase, ltered with 0.2 mm PTFE syringe lters and
injected directly into the HPLC. Gas chromatography/mass
spectrometric analysis (GC/MS) was performed for the three
street samples using the following conditions: HP-5 MS column
(30 m  0.25 mm, 0.25 mm), helium is the carrier gas owing at
a rate of 1.2 mL min1 and the following temperature gradient
program was adopted: starting with T ¼ 100 C, which ramped
linearly until 200 C, at a rate of 30 Cmin1, over 3.33 minutes,
with the temperature ramped further until 260 C, at a rate of
10 C min1, for 6.33 minutes, aerwards the temperature was
held constant for 10 minutes at 260 C.
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